false guidance

Coty Inc. faces securities fraud lawsuit after withdrawing $1B EBITDA guidance three months after promising it, with stock plunging 22% on corrective disclosures.

Pomerantz Law Firm files class action against $UPST and officers, alleging false statements about AI lending model accuracy. Stock fell 9.71% after November disclosure.

Portnoy Law Firm sues PayPal on behalf of investors, alleging management misled shareholders on revenue and growth targets before February earnings miss.

PayPal faces class action lawsuit after Q4 2025 earnings miss and withdrawal of 2027 targets triggered over 20% stock decline.

Levi & Korsinsky notifies Agilon Health shareholders of securities fraud lawsuit over false 2025 guidance; lead plaintiff deadline March 2, 2026.

Agilon Health faces securities class action over alleged 2025 guidance misstatements. Lead plaintiff deadline is March 2, 2026 for investors with losses.

Class action lawsuit filed against agilon health for allegedly making false statements about 2026 financial guidance and misrepresenting risk reduction initiatives' financial impact.

Class action lawsuits filed against PayPal for misleading revenue projections and REGENXBIO for concealing gene therapy safety concerns, both triggering significant stock declines.

Agilon Health faces class action lawsuit over false 2025 financial guidance. Lead plaintiff deadline set for March 2, 2026; eligible investors urged to apply.

Rosen Law Firm urges Agilon Health investors with losses over $100,000 to join securities class action before March 2026 deadline. Lawsuit alleges false financial guidance.

Portnoy Law Firm filed class action lawsuit against PayPal for allegedly issuing false revenue statements. Stock fell 20% after disappointing earnings and withdrawn 2027 guidance.

Class action lawsuit filed against agilon health for allegedly making false 2026 guidance claims and overstating financial benefits of risk-reduction initiatives, harming investors.

Agilon Health faces securities lawsuit over allegedly false 2025 guidance. Stock fell 51.6% after CEO termination and guidance suspension on August 4.

Class action lawsuit filed against agilon health for allegedly making false 2026 guidance claims and overstating benefits of risk reduction initiatives, affecting investors from February-August 2025.

Agilon Health faces securities class action lawsuit alleging materially false 2026 financial guidance and misleading statements about risk mitigation. Investors from February-August 2025 may participate.

AGL faces securities fraud allegations over false 2025 guidance. Stock plunged 51.5% after guidance suspension; investors have until March 2026 deadline to join class action.